PLENARY SESSION: TARGETING STEM/PROGENITOR PHENOTYPES FOR CANCER PREVENTION
8:00 a.m. to 10:00 a.m.
Chairperson: Thea D. Tlsty, University of California School of Medicine, San Francisco, CA
Implications of the Cancer Stem Cell Hypothesis for Early Detection and Prevention
Max S. Wicha, University of Michigan, Ann Arbor, MI
Bone Marrow-Derived Stem Cells: Implications for Cancer Prevention
Timothy C. Wang, Columbia University, New York, NY
Mechanisms of Genetic and Epigenetic (Tumor/Stem) Cell Plasticity
Thea D. Tlsty
CONCURRENT SESSIONS
10:15 a.m. to 12:15 p.m.
Diet and Cancer: Nutrigenomics
Chairperson: Christine B. Ambrosone, Roswell Park Cancer Institute, Buffalo, NY
Overview
Christine B. Ambrosone
Challenges in the Applications of –Omics Strategies in Nutrient-Gene Interaction and Cancer Prevention
Stephen Barnes, University of Alabama, Birmingham, AL
Folate and Colon Cancer: Epi, Genetics and Epigenetics
Cornelia M. Ulrich, Fred Hutchinson Cancer Research Center, Seattle, WA
New Nanotechnologies for Assessment of Biomarkers in Individual Cells
James S. Felton, UC Davis Cancer Center, Livermore, CA
Proffered Paper Presentation
Genetic Instability and Cancer Risk
Chairperson: Brian J. Reid, Fred Hutchinson Cancer Research Center, Seattle, WA
Overview
Brian J. Reid
A Mutator Phenotype in Human Cancers: Origins and Consequences
Lawrence A. Loeb, University of Washington, Seattle, WA
Genetic Instability and Clonal Evolution: Implications for Cancer Prevention and Cancer Risk Prediction
Carlo C. Maley, The Wistar Institute, University of Pennsylvania, Philadelphia, PA
From Biology to Clinic: Biomarkers of Genetic Instability
Li Mao, UT M. D. Anderson Cancer Center, Houston, TX
Proffered Paper Presentation
Novel Targets, Models, and Risk Groups in Lung Cancer Prevention
Co-Chairpersons: Paolo Boffetta, International Agency for Research on Cancer, Lyon, France and Jonathan M. Kurie, UT M. D. Anderson Cancer Center, Houston, TX
Inflammation and Immunity in Lung Tumorigenesis
Steven M. Dubinett, University of California, Los Angeles, CA
Role of the Tumor Microenvironment in the Promotion of Alveolar Epithelial Neoplasia Induced by Oncogenic KRAS
Jonathan M. Kurie
Contribution of Epidemiology to the Prevention of Lung Cancer
Paolo Boffetta
Novel Models of Lung Cancer
Kwok-Kin Wong, Dana-Farber Cancer Institute, Boston, MA
Proffered Paper Presentation
Prevention of Estrogen Receptor-Negative Breast Cancer
Chairperson: Powel H. Brown, Baylor College of Medicine, Houston, TX
Overview
Powel H. Brown
Epidemiology of ER-negative Breast Cancer
Susan Hankinson, Harvard Medical School, Boston, MA
Restoration of ER Expression and Anti-Estrogen Response in ER-Negative Breast Tumors: Strategies for Treatment and Prevention
Dorraya El-Ashry, University of Michigan, Ann Arbor, MI
Prevention of BRCA1-mediated Mammary Carcinogenesis by Targeting the Stabilized Progesterone Receptor with Anti-progesterone
Eva Y.-H. P. Lee, University of California, Irvine, CA
Preclinical and Clinical Studies for the Prevention of ER-negative Breast Cancer
Powel H. Brown
Proffered Paper Presentations
Prostate: Risk and Prevention
Chairperson: Howard L. Parnes, National Cancer Institute, Bethesda, MD
Overview
Howard L. Parnes
Associations of Obesity with Prostate Cancer Risk, Outcomes, and Trends
Alan P. Kristal, Fred Hutchinson Cancer Research Center, Seattle, WA
Oxidative Stress and DNA Repair in Prostate Carcinogenesis
Ashraful Hoque, UT M. D. Anderson Cancer Center, Houston, TX
Genotype and Phenotype Studies of Inflammation in the PCPT and Elsewhere
Elizabeth A. Platz, Johns Hopkins University, Baltimore, MD
Proffered Paper Presentation
PLENARY SESSION: CHALLENGES TO CHEMOPREVENTION AGENT DEVELOPMENT IN THE NEW ERA OF MOLECULAR TARGETING
1:00 p.m. to 3:00 p.m.
Co-Chairpersons: Richard L. Schilsky, University of Chicago, Chicago, IL, and Eva Szabo, National Cancer Institute, Bethesda, MD
Overview
Richard Schilsky
Preclinical Chemopreventive Agent Development
James A. Crowell, National Cancer Institute, Bethesda, MD
Challenges to Drug Development in the Era of Molecular Targeting: Clinical Chemoprevention Trials
Eva Szabo
Regulatory Challenges for Prevention Agent Development
Ann T. Farrell, Food and Drug Administration, Silver Springs, MD
Challenges to the Pharmaceutical Industry
Neil W. Gibson, OSI Pharmaceuticals, Inc., Farmingdale, NY
FORUM
3:15 p.m. to 4:00 p.m.
Challenges to Chemoprevention Agent Development in the Era of Molecular Targeting
Moderators: Richard Schilsky, University of Chicago, Chicago, IL and Eva Szabo, National Cancer Institute, Bethesda, MD
CONCURRENT SESSIONS
3:15 p.m. to 4:45 p.m.
Angiogenesis as a Target for Chemoprevention
Chairperson: John V. Heymach, UT M. D. Anderson Cancer Center, Houston, TX
Overview
John V. Heymach
Contribution of Pro-angiogenic Hematopoietic Cells to Revascularization
David K. Jin, Weill Medical College of Cornell University, New York, NY
Adaptation Mechanisms of Tumors in Response to Antiangiogenic Therapy
Gabrielle I. A. Bergers, University of California, San Francisco, CA
CXC Chemokines in Angiogenesis and Metastasis
Robert M. Strieter, University of Virginia, Charlottesville, VA
Biobehavioral Mechanisms and Cancer Progression
Chairperson: Susan K. Lutgendorf, University of Iowa, Iowa City, IA
Overview
Susan K. Lutgendorf
Neuroendocrine Regulation of Cancer Progression: Biological Mechanisms and Clinical Relevance
Anil Sood, UT M. D. Anderson Cancer Center, Houston, TX
Stress Management Intervention Effects on Biobehavioral Processes in Breast Cancer Patients Undergoing Medical Treatment
Mike H. Antoni, University of Miami, Miami, FL
Strategies to Prevent the Promotion of Tumor Metastasis by Surgery and Stress: From Animal Studies to Clinical Applications
Shamgar Ben-Eliyahu, Tel Aviv University, Tel Aviv, Israel
Melanoma: Prevention
Chairperson: Marianne Berwick, University of New Mexico, Albuquerque, NM
Overview
Marianne Berwick
Epidemiology and Genetics: New Results in Melanoma Etiology and their Application to Melanoma Prevention
Maria Theresa Landi, National Cancer Institute, Bethesda, MD
The Epigenetic Reprogramming of the Metastatic Melanoma Phenotype by the Microenvironment
Mary J. C. Hendrix, Northwestern Hospital, Chicago, IL
Proffered Paper Presentation
Radiolabeled Peptides for Melanoma Detection and Therapy
Yubin Miao, University of New Mexico, Albuquerque, NM
Novel Prevention and Treatment Strategies in Multiple Myeloma
Chairperson: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA
Overview
Kenneth C. Anderson
Risk Assessment, Progression, and Response Predictions Using a Custom Functional SNP Chip in Myeloma and Monoclonal Gammopathies
Brian Van Ness, University of Minnesota, Minneapolis, MN
Cytokine Involvement in the Prediction and Prevention of MGUS to Multiple Myeloma
John A. Lust, Mayo Clinic, Rochester, MN
Probing Immune Inflammation in Premalignancy
Madhav Dhodapkar, The Rockefeller University, New York, NY
AACR-CANCER RESEARCH AND PREVENTION FOUNDATION AWARD LECTURE
5:00 p.m. to 6:00 p.m.
Tobacco-Specific Lung Carcinogen: From Basic Research to Tobacco Control
Stephen S. Hecht, University of Minnesota Cancer Center, Minneapolis, MN
POSTER SESSION B
6:00 p.m. to 8:00 p.m.